Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase

作者: Irene Rappold , Lothar Kanz , Andrew C W Zannettino , Kari Alitalo , Sylvie Marchetto

DOI: 10.1182/BLOOD.V90.1.111

关键词:

摘要: The class III receptor tyrosine kinase FLT3/FLK2 (FLT3; CD135) represents an important molecule involved in early steps of hematopoiesis. Here we compare cell-surface expression FLT3 on bone marrow (BM) and cord blood (CB) cells using monoclonal antibodies (MoAbs) specific for the extracellular domain human FLT3. Flow cytometric analysis MACS-purified BM CB showed that 63% to 82% CD34+ 88% 95% coexpress Clonogenic assays morphological characterization FACS-sorted demonstrate colony-forming unit–granulocyte-macrophage (CFU-GM) immature myelo-monocytic precursor are enriched subpopulation staining most brightly with MoAb whereas majority burst-forming units-erythroid (BTU-E) small lymphoid morphology found FLT3− population. In contrast, statistically indistinguishable proportions CFU-granulocyte-erythrocyte-megakaryocyte-macrophage (CFU-GEMM) more primitive cobblestone area forming (CAFC) were detected both fractions, albeit FLT3+ fraction consistently CAFC activity than fraction. Although both, CD34+CD117+ (KIT+), CD34+CD90+ (Thy-1+), CD34+CD109+ FLT3, three-color phenotypic analyses consistent functional findings suggest defined as CD34+CD38−, CD34+CD71low, CD34+HLA-DR−, CD34+CD117low, CD34+CD90+, express low levels therefore not a significant extent bright versus negative sorting scheme. Thus, clear segregation progenitors from was confounded by apparent these cells, myeloid unambiguously segregated brightest erythroid dimmest. Additional MoAbs against progenitor/stem cell markers including mucinlike MGC-24v (CD164), kinases TIE, FMS (CD115), KIT (CD117) further illustrate differences surface antigen profiles cells. Notably, CD115 is rarely 20% 25% CD34+FLT3+ CD115+. Furthermore, 80% but only 60% 75% Only negligible amount CD34+CD19+ CB, while 30% presumed pro/pre-B CD34+CD164+ CD34+TIE+ subsets Analysis unseparated restricted subsets. About 65% 70% lymphocyte-gated CD34−FLT3+ positive monocytic marker consist CD10 expressing B-cell precursors. Finally, CD34− monocytes BM, PB granulocytes FLT3−. Our data show detectable appears first at multilineage progenitor disappears during stages development, upregulated maintained maturation. © 1997 American Society Hematology.

参考文章(50)
C Faul, G Klein, W Schuller, H J Bühring, H Schmidt, S Cole, X Zhu, S Armeanu, U Fritzsch, T Müller, I Rappold, A Ullrich, R Herbst, The adhesion molecule E-cadherin and a surface antigen recognized by the antibody 9C4 are selectively expressed on erythroid cells of defined maturational stages. Leukemia. ,vol. 10, pp. 106- 116 ,(1996)
R. E. Ploemacher, E. A. W. Blokland, S. Neben, D. A. Breems, Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia. ,vol. 8, pp. 1095- 1104 ,(1994)
O Rosnet, C Schiff, MJ Pebusque, S Marchetto, C Tonnelle, Y Toiron, F Birg, D Birnbaum, Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood. ,vol. 82, pp. 1110- 1119 ,(1993) , 10.1182/BLOOD.V82.4.1110.1110
Lyman Sd, Gruss Hj, Escobar S, Anderberg R, Brasel K, de Vries P, Expression of the flt3 receptor and its ligand on hematopoietic cells Leukemia. ,vol. 9, pp. 1212- 1218 ,(1995)
Leonie K Ashman, Antony C Cambareri, L Bik To, Roland J Levinsky, Christopher A Juttner, Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow Blood. ,vol. 78, pp. 30- 37 ,(1991) , 10.1182/BLOOD.V78.1.30.30
SD Lyman, L James, L Johnson, K Brasel, P de Vries, SS Escobar, H Downey, RR Splett, MP Beckmann, HJ McKenna, Cloning of the human homologue of the murine flt3 ligand : a growth factor for early hematopoietic progenitor cells Blood. ,vol. 83, pp. 2795- 2801 ,(1994) , 10.1182/BLOOD.V83.10.2795.2795
AM Turner, NL Lin, S Issarachai, SD Lyman, VC Broudy, FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood. ,vol. 88, pp. 3383- 3390 ,(1996) , 10.1182/BLOOD.V88.9.3383.BLOODJOURNAL8893383